Giant Cell Arteritis

Currently Recruiting

Protocol

Inclusion Summary

RAD201677

A multicenter, randomized, double blind, placebo-controlled, Parallel group study to evaluate the efficacy and safety of Sirukumab in the treatment of patients with giant cell arteritis

Able to receive Prednisone

ESR ≥ 50 mm/hour or CRP ≥ 2.45 mg/dL.

With 1 of either :

– cranial symptoms of GCA,
– Symptoms of PMR

With 1 of either :

– Temporal artery biopsy revealing GCA.
– Evidence of large-vessel vasculitis by angiography or imaging (MRA, CTA, US or PET-CT)

2. Active GCA within 6 weeks of Randomization